Share Twitter LinkedIn Facebook Email Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, @UCSFCancer offers her overall impression on the changing FLT3 inhibition landscape in acute myeloid leukemia (AML).
ASH 2025 AML Advances in 2026: PARADIGM Study, Menin Inhibitors, and Triplet Therapies for Acute Myeloid Leukemia Acute Myelogenous Leukemia 6 Mins Read
Joe Biden Prostate Cancer Timeline: When Did It Begin? Experts Weigh In Acute Myelogenous Leukemia 4 Mins Read
Transforming AML Treatment: The Breakthrough Precision and Speed of Dr. Gabriel Mannis, MD on the Notable Platform Acute Myelogenous Leukemia 1 Min Read